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INTRODUCTION: Patients with systemic lupus erythematosus (SLE) are at increased risk of 
the metabolic syndrome (MetS) and its complications. In the absence of published studies 
from sub-Saharan Africa, we investigated the prevalence and associations of the MetS 
amongst recent-onset SLE patients. 
METHODS: A cross-sectional study of recent onset (<5 years disease duration) patients with 
SLE meeting the SLICC SLE classification criteria. The MetS was defined by Joint Interim 
Statement criteria. Clinical and demographic data and a Functional Assessment of Chronic 
Illness Therapy score and the 36-Item Short-Form Healthy Survey were completed.   
RESULTS:  Of 75 patients, the mean age was 37.1 (11.7) years, disease duration was 30.8 
(23.6) months, 65 (86.7%) were female, 68.0% were of mixed ethnic ancestry and 29.3% 
were Black Africans. The mean SLEDAI score was 0.9 (1.6). The prevalence of MetS was 
40.0%, and age and body mass index were the only significant features associated with 
MetS (p = 0.003 and 0.001 respectively). Increased waist circumference (WC) was the most 
frequently observed feature, present in 92.9% of MetS patients. Patients with an elevated 
WC were 32.5 times more likely to have MetS.  
CONCLUSION: This study shows a high prevalence of MetS amongst South Africans with 
recently diagnosed SLE. This calls for aggressive strategies to reduce the prevalence of Mets 
and atherosclerotic cardiovascular disease. Waist circumference is a useful and cost-
effective screening tool to identify SLE patients at risk of MetS. 
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW  
 
Systemic lupus erythematosus is a multi-systemic autoimmune disease with numerous 
clinical manifestations, and a spectrum of severity as well as alternating phases of remission 
and flares. It commonly affects the skin, joints, kidneys and neurological system.(1) The 5-
year survival of patients with SLE  has improved from 50% in 1950 to over 95% in 2010.(2).  
Despite advances in therapies and improved outcomes in the last few decades, mortality 
and morbidity  associated with SLE remains 3 times higher than that of age- and sex-
matched healthy persons(3). Several studies have shown that lower socioeconomic status is 
related to higher morbidity and mortality patients with SLE(4) (5, 6) 
As described by Urowits in 1972, mortality amongst SLE patients has a bimodal pattern. 
Early deaths were caused by active inflammation of major organs, particularly renal and 
neurological disease, together with infection, and the late deaths in the disease (a mean 8.6 
years after symptom onset) were attributable to atherosclerotic cardiovascular (ASCV) 
events (7).  Subsequent studies have confirmed this increased risk of ASCV disease in SLE, 
particularly amongst young females (8, 9). Manzi et al showed that the incidence of 
myocardial infarction in women with SLE aged 35-44 years is over 50 times greater than in 
women of similar age (10). 
The explanation for the marked increase in risk for ASCV in SLE is probably multifactorial and 
may differ for cardiovascular and cerebrovascular events. Immune complex–induced 
endothelial damage, vasculitis, antiphospholipid antibody–induced thrombosis, Libman-
Sacks endocarditis, hypertension from renal involvement or corticosteroid therapy, and 
corticosteroid-induced central obesity, hyperglyceamia, or hypercholesterolemia are likely 
to all contribute (11).  
The ATP111 Framingham risk score  is used to estimate the 10-year risk for ASCV including 
coronary heart disease, stroke, transient ischemic attack and heart failure (12) and is 
recommended as a tool to guide the management of dyslipidaemia by the South African 
(SA) Heart Association and Atherosclerotic Society of SA (13). However, it has become clear 
that the risk for ASCV in SLE patients cannot be fully explained the traditional Framingham 
risk factors (14, 15).  
Several studies have suggested that impaired endothelial function is the principal driving 
force behind the accelerated atherosclerosis in SLE (16, 17). Patients with clinically 
quiescent SLE have also been shown to have reduced small artery elasticity, resulting in 
impaired endothelial function (14). The most recent literature has focused on endothelial 
progenitor cells (EPCs). These EPCs play a key role in the repair of vascular damage, and it 
has been suggested that decreased numbers of this population are associated with an 
increased risk of ASCV Disease, and even with preclinical atherosclerosis (18). The numbers 
and function of peripheral blood EPCs amongst SLE patients are significantly reduced 
suggesting that this cell population could potentially be involved in the development of 
premature atherosclerosis in this disease. 
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The metabolic syndrome (MetS) is a cluster of metabolic abnormalities associated with 
central adiposity and insulin resistance that increase the risk of ASCV.The key components 
of MetS are abdominal obesity, atherogenic dyslipidaemia, raised blood pressure and insulin 
resistance with glucose intolerance (19). There are various criteria used to define the MetS 
(Table 1). The recommendations set by the Joint Interim Statement (JIS) are the most 
preferred as they have been broadened to include cut-off values for  both Europeans and 
non-Europeans as a consensus definition which can be adapted for the African population 
(20). 
Mok et al reported an increased risk of premature ASCVD after adjustment for age and 
other vascular risk factors not included in the MetS (21).  
 At first glance, ASCV is a disease of affluence, and was once uncommon in sub-Saharan 
Africa. Over the last three decades, economic and lifestyle transformation including 
urbanisation and adoption of “western lifestyle” have taken place in sub-Saharan Africa. 
Thus, despite widespread poverty, the prevalence of the MetS is increasing and ASCV is 
emerging as a major cause of mortality (22) . 
A high prevalence of MetS has been documented in an urban mixed ethnic ancestry 
population in the Western Cape. According to the JIS definition, 62% of adults over 31 years 
had MetS, with females particularly affected (23). Elsewhere, then Mets has been shown to 
have an inverse relationship with low socio-economic status (24).  One factor contributing 
to this may be the dietary choices of low income households such as energy-dense, highly 
palatable foods that provides maximum calories per volume at the least cost. Interestingly, 
low house hold income may increase the risk of MetS in gender specific manner, with 
women more affected than men(25),(26). 
Several studies have reported a higher prevalence of MetS amongst SLE patients compared 
to the general population (Table 2). Studies from  first world European countries have report 
a prevalence of MetS ranging between 16% and 22%, whereas developing countries have a 
much  higher  prevalence  of 38.2% Puerto Rico and as high as 45.2% in Brazil(26) (27, 28).  
Systemic Lupus Erythematosus is a state of chronic inflammation due to over-production of 
pro-inflammatory factors  including interleukin-6( IL-6), C-reactive protein( CRP), leptin, 
plasminogen activator inhibitor -1 (PAI-1), erythrocyte sedimentation rate (ESR) and tumour 
necrosis factor alpha (TNF -a) . 
There are various mechanisms  implicated in the pathogenesis of endothelial dysfunction in 
MetS. Recent attention has focused on the imbalance of arterial vasoactive substances. 
Decreased nitric oxide (NO) availability appears to play a major role and may result from 
reduced NO production and/or increased inactivation by reactive oxygen species(29, 30)  In 
addition, reduced availability of other vasodilating agents (such as  prostacyclin and 
endothelium-derived hyperpolarizing factors) and/or increased production or activity of 
vasoconstrictive substances (including endothelin-1 and angiotensin II) are also 
implicated. All the components of MetS can individually impair endothelial function(29, 31). 
Some studies have reported higher levels of these inflammatory markers  such as 
homocysteine and CRP in patients with SLE with MetS (21, 32). 
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Impaired peripheral blood EPC function is associated with the MetS together with 
significantly elevated serum uric acid and inflammatory biomarkers, including homo-
cysteine, IL-8, sICAM-1 or complement molecules, in SLE patients with MetS (18). A positive 
association between increased arterial stiffness and MetS has been reported. One recent 
study demonstrated that SLE patients with and without MetS differed significantly regarding 
arterial stiffness, with the average aortic pulse wave velocity (PWV) significantly higher in 
the MetS group compared to the non-MetS group (33). There is a close link between the 
presence of MetS and increased arterial stiffness, even when PWV determination was 
adjusted for age and BP.(9) . SLE patient with MetS  have higher levels apolipoprotein-
B(Apo-B)  which has been shown to be  an independent predictor of arterial stiffness.(34). 
MetS and its components  may influence levels of adipokines such leptin(35) . Amongst SLE 
patients with Mets, increased leptin levels have close correlation with subclinical 
atherosclerosis as measured by carotid intima media thickness (8). 
Current treatment recommendations for the management of MetS are targeted at the 
general population and focus on two key  therapeutic goals. These include weight 
management and increasing physical activity together with  optimal medical management 
of cardiovascular risk factors if they persist despite lifestyle modification (36, 37). The risk of 
development of type 2 diabetes and the levels of risk factors for ASCV can be substantially 
reduced by lifestyle modification. In a study conducted by The Diabetes Prevention 
Program, both intensive lifestyle intervention and the addition of metformin therapy were 
effective for prevention of MetS in patients who did not have the syndrome at baseline(38). 
Metformin may also reduce the incidence of diabetes- related endpoints such as fatal 
myocardial infarction or sudden death, fatal stroke, or death from peripheral vascular 
disease, renal disease and  hyper/hypoglycaemia.(39) Although not strictly addressing the 
MetS, the 4S trial of lipid lowering with simvastatin showed that amongst patients with 
elevated serum LDL cholesterol and established coronary disease, those with MetS had both 
the highest risk of major coronary events and greatest benefit (48% risk reduction) from 
statin therapy (40, 41).  
There is some debate regarding  the use of low dose aspirin in patients with SLE and MetS as 
primary prophylaxis. It has been suggested that patients with SLE should receive low-dose 
aspirin prophylaxis only if they have certain risk factors such  as risk factors for ASCVD or 
previous history of ASVD or  positive anti-phospholipid antibodies(42). Reinforcing this, a 
recent Italian study showed that low-dose aspirin is a safe treatment and may be beneficial 
in the primary prophylaxis of ASCV events in SLE patients.)(43). 
More research is needed to evaluate the role of lifestyle modification and pharmaco-
prevention for diabetes in SLE patients with or without Mets, and interventions focusing 
specifically on managing the MetS and reducing ASCVD in patients with SLE. To date, there 
are no published studies on MetS in sub-Saharan Africans with SLE. This study aims to 
determine the prevalence and associations of MetS in adults with recent onset SLE in the 




Table 1: Comparison of the diagnostic criteria for the Metabolic Syndrome  
 
MetS: Metabolic syndrome; IDF:  International Diabetes Federation; NCEP ATP III: National Cholesterol 
Education Program Adult Treatment Panel III; JIS: Joint Interim Statement on MetS ; AHA/NHLB: American 






Components NCEP-ATP III(44)  AHA/N(36) IDF(45) JIS(20) 
 Number of 
components 
for diagnosis 
















≥102 cm (men) ≥102 cm (men) ≥94 cm (men) ≥94 cm (men) 
 
≥88 cm (women) ≥88cm (women) ≥80 cm (women) ≥80 cm (women) 
Blood pressure ≥130/85 mm Hg ≥130/85 mm Hg or 
receiving treatment 
≥130/85 mm Hg or 
receiving treatment 
≥130/85 mm Hg or 
receiving 
treatment 
Triglycerides ≥1.7 mmol/L ≥1.7 mmol/L or 
receiving treatment 
≥1.7 mmol/L or 
receiving treatment 






<1.0 mmol/L (men) 
<1.3 mmol/L 
(women) 

















Table 2: Global prevalence of MetS in patients with SLE 
 
 
Abbreviations: MetS: Metabolic syndrome ; IDF:  International Diabetes Federation ; NCEP ATP III: 
National Cholesterol Education  Program Adult Treatment Panel III; WHO: World Health Organisation; 
JIS: Joint Interim Statement on MetS ; AHA/NHLB: American Heart Association /National Heart, Lung 
,and Blood Institute 
Country, year of publication  MetS criteria Age (SD ) (yrs) Disease 
duration - mean 
(yrs) 
Prevalence MetS n, (%) 
Iran,2018(46) NCEP/ATPIII 
IDF 
41.0 (12.2) 6.5 33/73 (45.2) 
34/73 (46.6) 
Italy,2017(47) IDF 47.5 (14.1) 9.9  34/100 (34.0) 
(48) 
 
Metanalysis  NA  NA  26 (CI 0.25-0.27) 
Brazil,(49) NCEP/ATPII 41.7(2.5) 11.9 66/146(45.2) 
Turkey,(50) NCEP/ATPIII 40.2(13.5) 4.6 58/311(19.0) 
Multinational,2015 (51) JIS  34.9 (13.6)  0.5 439/1150 (38.2) 
(52) WHO 1999 definition 
Consensus definition 








(53) JIS 31.0(5.5) 10.6 23/103(22.3) 
Egypt, 2015 (54) (NCEP/ ATP III) 32.9 (8.5) 3.4 12/30 (40.0) 
 Peru,2014 (55) JIS   44.6 (12.9) 7.6 42/117 (44.4) 
China,2013 (56) JIS   34.1 (11.1) 2.9- 40/116 (34.2) 
Egypt, 2013 (57) (ATP III) 30.2 (8.3) 5.8 34/92 (36.9) 
UK,2011(58) JIS  48.0 (42-58) 8.5  60/200 (30.0) 
Italy,(28) IDF 38.8(11.2) 8.5 
52/162(32.1) 
Spain (26) AHA/NHLB 43.6(13) 8.7 87/204(38.2) 
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INTRODUCTION: Patients with systemic lupus erythematosus (SLE) are at increased risk of the 
metabolic syndrome (MetS) and its complications. In the absence of published studies from sub-
Saharan Africa, we investigated the prevalence and associations of the MetS amongst recent-
onset SLE patients. 
METHODS: A cross-sectional study of recent onset (<5 years disease duration) patients with SLE 
meeting the SLICC SLE classification criteria. The MetS was defined by Joint Interim Statement 
criteria. Clinical and demographic data and a Functional Assessment of Chronic Illness Therapy 
score and the 36-Item Short-Form Healthy Survey were completed.   
RESULTS:  Of 75 patients, the mean age was 37.1 (11.7) years, disease duration was 30.8 (23.6) 
months, 65 (86.7%) were female, 68.0% were of mixed ethnic ancestry and 29.3% were Black 
Africans. The mean SLEDAI score was 0.9 (1.6). The prevalence of MetS was 40.0%, and age and 
body mass index were the only significant features associated with MetS (p = 0.003 and 0.001 
respectively). Increased waist circumference (WC) was the most frequently observed feature, 
present in 92.9% of MetS patients. Patients with an elevated WC were 32.5 times more likely to 
have MetS.  
CONCLUSION: This study shows a high prevalence of MetS amongst South Africans from the 
Western Cape who were mostly of mixed ancestry, with recently diagnosed SLE which was 
uncomplicated and had low disease activity . This calls for aggressive strategies to reduce the 
prevalence of Mets and atherosclerotic cardiovascular disease. Waist circumference is a useful and 
cost-effective screening tool to identify SLE patients at risk of MetS. 
 






Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease, associated 
with an increased risk of atherosclerotic cardiovascular disease (ASCVD), with an incidence 
of myocardial infarction in affected women aged 35-44 years over 50 times greater than in 
healthy women of the same age (10). Recent studies have reported an increased risk of 
premature cardiovascular disease after adjustment for age and traditional vascular risk 
factors (8, 9, 21, 60). 
The metabolic syndrome (MetS) is a cluster of metabolic abnormalities associated with 
central adiposity and insulin resistance (45). This syndrome leads to endothelial dysfunction, 
arterial stiffness and accelerated ASCVD (18, 33, 61). Patients with systemic lupus 
erythematosus (SLE) have been shown to have a higher burden of the MetS than healthy 
controls.(53, 58, 62, 63) 
At first glance, MetS was perceived as  a disease of affluence, and was once uncommon in 
sub-Saharan Africa(64). Over the last three decades, lifestyle changes associated with 
urbanisation  have taken place and, despite widespread poverty, the prevalence of the MetS 
is increasing and ASCV is emerging as a major cause of mortality (22). Recently, a high 
prevalence of MetS was documented in an urban population of mixed ethnic ancestry in the 
Western Cape where 62.0% of adults over 31 years had MetS, with females particularly 
affected (23).  
To date, there are no published studies on MetS in sub-Saharan Africans with SLE. This study 
was undertaken to determine the prevalence and associations of MetS in adults with recent 
onset SLE in the Western Cape, South Africa. 
Patients and Methods 
This cross-sectional study recruited patients from the rheumatology clinic in a state-sector 
academic hospital as part of the African Lupus Genetics Network, a prospective database of 
SLE patients (65). All patients met the following inclusion criteria: adults (≥18 years); 
symptom onset within the last 5 years; and fulfilled the Systemic Lupus International 




Approval for the study was obtained from the University of Cape Town Human Research 
Ethics Committee, and all patients signed informed consent before participating in the 
study. 
Demographic data, clinical details including comorbidities, therapy and bio-morphometric 
details were collected.  Serum lipid lipogram results including total cholesterol, triglyceride 
(TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol 
(HDL-C) were documented. In addition, patients completed a Functional Assessment of 
Chronic Illness Therapy (FACIT) score measuring fatigue and the 36-Item Short-Form Health 
Survey (SF-36 )as a general measure of health-related quality of life (HRQoL)(67). The MetS 
was defined according to the JIS criteria, using WC cut-offs of male >94 cm, female> 80 cm 
(20).  
Statistical methods 
The Students t-test was applied to compare continuous variables between groups, except 
where the data showed a non-normal distribution, in which case the Wilcoxon rank sum test 
was used. The Chi-square test, or where indicated, the 2-tailed Fishers’ exact test was used 
in the case of categorical variables. A bivariate logistic regression model was constructed to 
assess the association between specific variables (socio-demographic, clinical and 
treatment) and MetS. Significant variables found in the univariate analyses and chi-square 
contingency tests were entered the logistic regressions. A p-value of 0.05 was considered 
significant. Statistical analyses were done using SPSS version 24.  
Results  
Of 75 patients, 86.7% were female, and of these 58.5% were premenopausal, the mean (SD) 
age was 37.1 (11.7) years and disease duration was 30.8 (23.6) months (Table 1). In terms of 
ethnicity, 68.0% were of mixed ethnic ancestry and 29.3% were black Africans and 2.7% 
were Caucasian. Patients were of poor socio-economic background: the mean (SD) highest 
level of schooling was 10.0 (2.6) years, and 30.7% were unemployed.  
 
The SLE disease activity index (SLEDAI) and Systemic Lupus International Collaborating 
Clinics damage index were low (0.9 (1.6) and 0.3 (0.7) respectively). The SF-36 scores 
showed poor physical and mental health, with low FACIT scores suggesting a high burden of 
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fatigue,a sedentary lifestyle may have contributed to the background prevalence of 
metabolic syndrome . The mean (SD) body mass index (BMI) was 30.3 (23.6) kg/m2, over a 
third of patients were smokers. Two thirds had been exposed to corticosteroids.  
 
The prevalence of MetS in this cohort was 40.0%, and patients with MetS were significantly 
older than patients without MetS (mean age 41.9 vs 33.8 years, p =0.003), and had a higher 
BMI (mean BMI 30.3 vs 25.7 kg/cm2, p =0,001) (Table 1). More patients in the MetS group 
were unemployed (47.8% vs 26.7%), although this did not reach statistical significance.   
The feature of the MetS most commonly encountered was an elevated WC, present in 
92.9% of those with MetS (Table 2). Elevated TG and low HDL-C were also significantly 
associated with the MetS (p <0.001 and 0.008 respectively). Multivariate analysis showed 
that only elevated waist circumference, elevated blood pressure, and low HDLC were 
independently associated with the MetS, encountered in 74.1% of MetS patients (p < 0.001, 
Nagelkerke R2 =0.74).  
 
Discussion 
This study,is the first study to our knowledge assessing a cohort of SLE patients with MetS in 
sub-Saharan African, shows that 40.0% of South African patients in the Western Cape  with 
recent-onset SLE fulfilled criteria for the MetS. This high prevalence of the MetS is similar to 
that reported in low and middle-income countries (LMIC) of patients with SLE with disease 
duration less than 10 years (Table 3). A lower prevalence of MetS has been reported in 
higher income European countries. While these differences may reflect variations in the 
diagnostic criteria, other explanations might include genetic susceptibility or environmental 
factors,sedentary lifestyle and a high calorie diet (48, 58).  
 
Most of the patients in our study were young women of poor socioeconomic status, with 
over a third of patients unemployed, and dependant on a state disability grant. Several 
other studies have shown that a lower socioeconomic level is associated with MetS (27, 68). 
The high prevalence of smoking (36%) is a concern. A South African study demonstrated a 
high smoking prevalence and a 50% higher overall smoking-related mortality in patients of 
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mixed ethnic ancestry compared to other race groups, with ASCVD a major cause of death 
(69).       
Many studies have looked at the factors that predispose SLE patients to developing MetS. 
The present study found only age and BMI to be significant, with no association with disease 
activity, damage scores or therapy. A recent study in South India, no association was found 
between the MetS, SLE disease activity or damage scores (52). Several studies have shown 
no association with steroid use (28, 62, 63). In contrast, a Brazilian study of  premenopausal 
SLE women showed that MetS was associated with a higher cumulative dose of steroids 
(53). In addition, we demonstrated no association between MetS and HRQoL or fatigue. A 
recent Italian study demonstrated that SLE  patients with MetS report low mood and 
physical inactivity, and have a  poor HRQoL  in both mental and physical components (47). 
Elevated WC was the most common component of the MetS. In our study 57.3 % of the 
total number of patients with elevated WC had MetS, and patients with an elevated WC 
were 32.5 times more likely to have MetS than those with a normal WC. Elsewhere, studies 
of SLE patients have shown WC to be an important feature of the MetS (62, 63, 70). 
Similarly, in the general population of the Western Cape, elevated WC was  the most 
commonest feature of the MetS, and was shown to be a better predictor than BMI of ASCVD 
risk in the general population in a US cohort of patients (23, 71). Hence, WC could be a 
useful and cost-effective screening tool to identify those at risk of MetS. 
 
Dyslipidaemia, specifically a reduced HDL-C, was the second most common occurring 
feature in our study, again similar to the findings of other studies. Of concern, HDL can lose 
its anti-inflammatory properties in states of chronic inflammation, and instead become pro-
inflammatory (piHDL). In a study in California, 45.0% of women with SLE were found  to 
have the dysfunctional piHDL, increasing the risk of subclinical atherosclerosis (72). 
 
Limitations of our study include the cross-sectional design, the small number of patients 
included, and the lack of a healthy control group. In addition, we were unable calculate 
patients’ cumulative prednisone dose. We plan to expand and follow this cohort for the 
development of ASCVD. 
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In conclusion, we have shown a high prevalence of MetS amongst South Africans in the 
Western Cape  with recently diagnosed SLE. This, together with the high prevalence of 
cigarette smoking, and SLE disease itself, infers a particularly significant risk of ASCVD. 
Future interventional studies addressing modifiable risk factors such as weight loss, smoking 
cessation and physical activity in this population are planned. Waist circumference is a 
useful screening tool for identifying those at risk of MetS and should be incorporated into 
the routine assessment of SLE patients. 
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*Comparing patients with MetS to those without MetS 
** Odds Ratio only reported for categorical variables 
ns: not significant; MetS: Metabolic syndrome; SLEDAI: SLE disease activity index; SLICC: Systemic Lupus International Collaborating Clinics; MCS Mental Composite Score; PCS: Physical 
Composite Score FACIT: Functional Assessment of Chronic Illness Therapy;  




No MetS  
(n= 45) 
p-value* OR (95% CI)** 
Age (years)(mean, SD)  37.1 (11.7) 41.9 (10.1) 33.8 (11.6) 0.003  
Female n (%) 65 (86.7) 28 (93.3) 37 (56.9) ns 3.0 (0.6 – 15.3) 
Postmenopausal n (%) 5 (7.7) 4 (16.0) 1 (2.5) ns 
 
Ethnicity (self-reported)- n (%)      
Black African 22 (29.3) 7 (23.3) 15 (33.3) ns  
Mixed ancestry 51 (68.0) 22 (73.3) 29 (64.4) ns  
White 2 (2.7) 1 (3.3) 1 (2.2) ns  
      
Disease duration (months)(mean, SD) 30.8 (23.6) 29.9 (18.8) 31.5 (27.0) ns    
Highest level schooling (years) (SD) 10.0 (2.6) 9.9 (2.7) 10.1 (2.6) ns  
Unemployed n (%) 23 (30.7) 11 (47.8) 12 (26.7) 0.10 1.6 (0.6 – 4.3) 
Body Mass Index (kg/cm2) (mean, SD) 27.6 (5.9) 30.3 (4.7) 25.7 (6.1) 0.001  
Cigarette smoking (current) n (%) 27 (36.0) 12 (40.0) 15 (34.1) ns 1.3 (0.5 – 3.4) 
SLEDAI score (mean, SD) 0.9 (1.6) 0.7 (1.1) 1 (1.8) ns  
SLICC damage index (mean, SD) 0.3 (0.7) 0.3 (0.5) 0.3 (0.8) ns  
Corticosteroids ever prescribed n (%) 50 (66.6) 20 (66.6) 30 (66.6) ns 0.9 (0.3 – 2.4) 
Corticosteroid dose n (%)    ns 0.7 (0.2 – 2.7) 
Low (≤ 10 mg) 37/48 (77.1)  17/20 (85.0)  20/28 (71.4)  ns  
High (>10 mg) 11/48 (22.9) 4/20 (20.0) 7/28 (25.0) ns  
SF-36 PCS (mean score) (mean, SD) 39.1 (19.8) 39 (20.1) 39.2 (19.9) ns  
SF-36 MCS (mean score) (mean, SD) 43.1 (24.7) 41.1 (26.9) 44.5 (23.3) ns  
FACIT score (mean, SD) 28.1 (12.4) 26.5 (12.8) 29.2 (12.2) ns  
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*Comparing patients with MetS to those without 













Univariate analysis* Multivariate analysis* 
    
OR (95% CI) p-value OR (95% CI) p-value 





circumference n (%) 




32.5 (6.5-163.3) <0.001 0.01 (0.01-0.61) 0.03 
Elevated triglycerides or 





5/39 (12.8) 7. 3 (2.2-23.9) <0.001 0.07 (0.01 – 1.36) 0.08 
Reduced HDL-C or on 
drug therapy n (%) 




4.0 (1.4-11.6) 0.008 0.04 (0.0.1 – 0.85) 0.04 
Elevated blood pressure 
or on drug therapy n (%) 
20 (26.9) 15 (50.0) 9/44 (20.5) 3.9 (1.4-10.8) 0.008 0.04 (0.01 – 1.03) 0.05 
Elevated fasting glucose 
or drug therapy n (%) 




Table 3: Global prevalence of MetS in patients with SLE with recent-onset SLE (disease duration 





MetS: Metabolic syndrome ; IDF:  International Diabetes Federation ; NCEP ATP III: National 
Cholesterol Education  Program Adult Treatment Panel III; JIS: Joint Interim Statement on MetS ; 










Country, year of 
publication 









41.0 (12.2) 6.5 33/73 (45.2) 
34/73 (46.6) 
Italy,2017(47) IDF 47.5 (14.1) 9.9  34/100 (34.0) 
Multinational,2015 (51) JIS  34.9 (13.6)  0.5 439/1150 (38.2) 
Egypt, 2015 (54) (NCEP/ ATP III) 32.9 (8.5) 3.4 12/30 (40.0) 
 Peru,2014 (55) JIS   44.6 (12.9) 7.6 42/117 (44.4) 
China,2013 (56) JIS   34.1 (11.1) 2.9 40/116 (34.2) 
Egypt, 2013 (57) (ATP III) 30.2 (8.3) 5.8 34/92 (36.9) 
UK,2011(58) JIS  48.0 (42-58) 8.5  60/200 (30.0) 
Nederlands,2008 (59) AHA/NHLB 39.0 (12) 6.6  22/14 (16.0) 
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CHAPTER 3 APPENDICES  
Questionnaire/data capture instrument 
Folder number: 
Name and surname  
Contact details: 
Demographics 
• SEX:    
• DOB :  
• AGE: 
• ETHNIC GROUP: 
• HIGHEST LEVEL OF EDUCATION  
• EMPLOYEMENT  
Clinical background  
DATE OF SYMPTOM ONSET 
DATE OF DIAGNOSIS  
MENOPAUSAL STATUS  
SMOKER HISTORY 
 HYPERTENSION : 
Clinical assessment  
HIEGHT:                                                                 WEIGHT:   kg                                BMI kg/m2 
WAIST CIRCUMFERENCE:                                cm      
HIP CIRCUMFERENCE:                                        cm  
HIP –WAIST CIRC : 
BLOOD PRESSURE SYSTOLIC/ DYSTOLIC  ___________mmHg    
TOTAL CHOLESTEROL mg/dl  TRIGLYCERIDES _______mmHg 
HDL- CHOLESTEROL _________mmHg      HbA1c _________mmol/l 
Treatment /medication  
• CHLOROQUINE    
• STATIN USE  
• PREDNISONE USE  




Study Title:  Metabolic Syndrome in patients with systemic lupus erythematosus attending Groote 
Schuur Hospital? 
I, ____________________________________________________________________  ,  agree to 
participate in this study that will examine  details of my medical history( especially sugar diabetes 
and high blood pressure , together with  my weight, waist and hip measurements  , height and  body 
mass index , calculated as weight in kilograms (kg) and divided  by the square  height in metres -
kg/m2) 
I understand that this study will also look at the results of blood samples taken to measure total 
cholesterol, high density lipo-protein cholesterol (HDL), low density lipo-protein(LDL) and 
triglycerides . 
I understand that this test is required as part of my routine visits to the clinic, and is not performed 
only for this study. 
The results of this study will be made known to me, via my doctor, in accordance with the relevant 
protocol, if and when available.  
In addition, I authorise that they may be made known to other doctors involved in my care. 
I have been informed that:  
• There are risks and benefits associated with analysis and these have been explained to me.  
• Even under the best conditions, current technology of this type is not perfect and could lead 
to incorrect results.  
• Where biological material is used for research purposes, there may be no direct benefit to 
me. 
I understand that I may withdraw my consent for any aspect of the above at any time without this 
affecting my future medical care.  
ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND AND MY 
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The metabolic syndrome (MetS) is a cluster of metabolic abnormalities associated with 
central adiposity and insulin resistance that increase the risk of atherosclerotic 
cardiovascular events (ASCV).The key components of MetS are abdominal obesity, 
atherogenic dyslipideamia, raised blood pressure and insulin resistance with glucose 
intolerance.(45) In the developed world, patients with Systemic lupus erythematosus (SLE) 
have been shown to have a higher burden of the metabolic syndrome (MetS) than healthy 
controls. 
A bimodal pattern of mortality in SLE was described by Urowits in 1972, based on his 
observations of a Canadian cohort of SLE patients followed over 10 years(7).Active 
inflammation of major organs, particularly renal and neurological disease, together with 
infection, caused death early in the disease. Late deaths (a mean 8.6 years after symptom 
onset) were attributable to atherosclerotic cardiovascular (ASCV) events. Subsequent 
studies have confirmed this increased risk of ASCV disease in SLE, particularly amongst 
young females. Manzi et al (10)showed that the incidence of myocardial infarction in 
women with SLE aged 35-44 years is over 50 times greater than in women of similar age. 
 
Metabolic syndrome may lead to endothelial dysfunction and accelerated ASCVD in SLE 
patients. Recently, MetS-associated impaired peripheral blood endothelial progenitor cell 
function is described(18)  together with significantly elevated serum uric acid and 
inflammatory biomarkers, including homo-cysteine, IL-8, sICAM-1 or complement  SLE 
patients with MetS. Not surprisingly, SLE patients with MetS have been shown to have 
arterial stiffness(18, 33, 61).Of major concern, SLE is associated with an increased risk of 
premature cardiovascular disease due to accelerated atherosclerosis over and above 
traditional risk factors included in the MetS.Mok and colleagues reported an increased risk 
of premature cardiovascular disease after adjustment for age and other vascular risk factor 
not included in the syndrome(21) 
At first glance, MetS is a disease of affluence, and was once uncommon in sub-Saharan 
Africa. Over the last three decades, economic and lifestyle transformation including 
urbanisation and adoption of “western lifestyle” have taken place in sub-Saharan Africa. 
Thus, despite widespread poverty, the prevalence of the MetS is increasing and ASCV is 
emerging as a major cause of mortality(22). A high prevalence of MetS has been 
documented in an urban population of mixed ancestry in the  Western Cape(23) according 
to the Joint Interim Statement (JIS) of the IDF/NHLBI/AHA/WHF/IAS/IASO definition (73), 
62% of adults over 31 years had MetS, with females particularly affected.(74) 
To date, there are no published studies of the prevalence or associations of the MetS in sub-
Saharan Africans with SLE. This study will be undertaken to determine the prevalence of 







1. To measure the prevalence and  associations of the MetS a defined by Joint 
Interim Statement (JIS) in SLE patients with recent onset SLE (<5 years disease 
duration).    
The secondary objectives are: 
2.   To document the treatment practices of patients with SLE, use of low dose 
aspirin and the use chloroquine. 
 
PATIENTS AND METHODS  
 
This cross-sectional study will enrol 105 patients onto a prospective SLE database, ALUGEN 
(African Lupus Genetics Network). Patients will be  enrolled from Groote Schuur Hospital 
(GSH) rheumatology outpatient department, and will meet the following inclusion criteria: 
SLE according to SLICC 2012 criteria(66),age greater than 18 years old, SLE diagnosis less 
than or equal to 5 years ago and signed informed consent to participate in  the study. 
Demographic data, clinical details of organ-specific involvement, comorbidities, therapy and 
bio-morphometric details will be collected with a special focus on the following factors: 
1. Participants details and contact details (name, surname date of birth, gender and 
ethnic background (self-reported) 
2. Disease history including past or present history of smoking, family history of 
premature coronary heart disease  
3. Clinical features of organ involvement (constitutional, skin, musculoskeletal, 
cardiovascular, neuropsychiatric, renal, ocular, haematological, immunological, 
and gastrointestinal system. 
4. Obstetric history and menopausal status (females only) 
5. Medication details including the current use and doses of corticosteroids 
(prednisone), chloroquine, statin and low dose aspirin.  
MetS will be defined according to the JIS criteria(20)  
STATISTICAL METHODS  
The Students t test will be applied to compare continuous variables between groups, except 
where the data shows a non-normal distribution, in which case the Wilcoxon rank sum test 
will be  used. The Chi-square test, or where indicated, the 2-tailed Fishers’ exact test will be 
used in the case of categorical variables. Spearman correlation coefficients will be applied to 
assess correlations between continuous variables. We will perform Multivariate analysis  
using stepwise backward logistic regression, and demographic and baseline variables with a 
p-value ≤ 0.15 in the univariate analysis will be  included in the model. A p-value of 0.05 will 
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be considered significant. All statistical analyses will done using Stata 10 software 
(StataCorp, USA). 
ETHICAL CONSIDERATIONS 
Ethical approval for the ALUGEN database has already been obtained from the joint Groote 
Schuur Hospital and University of Cape Town Research Ethics Committee (REC) (535/2010). 
An amendment has been be submitted for this sub-study. 
Consent to enter the study will be sought from each participant only after a full explanation 
has been given, and time allowed for consideration (Appendix A). Signed participant consent 
will be obtained.  The right of the participant to refuse to participate without giving reasons 
will be respected. 
The Principal investigator and all investigators on the study will preserve the confidentiality 
of participants taking part in the study in compliance with data protection legislation. 
Anonymity will be ensured with the use of a master code which will be kept in a separate 
secure filing cabinet. All computers will be password protected.  
 
TIMING: 
The study will run retrospectively from September of 2015. 
• Protocol will be submitted to the Postgraduate Committee in April 2016. 
• Ethics submission will be in May 2016. 
• Data analysis will be completed in January 2018. 
• Manuscript preparation and completion will be accomplished by 30th of 
July 2018 for submission for publication. 
 
The study will be carried out according to the following Gantz chart: 
 
 2015- 2017 April May Jun Jul Aug Sep Oct Nov Dec 
Protocol 
assessment 
         
Data 
Collection    









There are no anticipated costs to the hospital or participating patients arising from this 
study. Blood investigations and physical assessments performed at the SLE clinics on all 
patients as part of routine clinical care. Statistical analysis and any administrative costs 
(printing, photocopies and telephone calls) will be covered by an NRF Thuthuka grant held 
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